Ovation ScienceOVATF EBITDA Margin % is -645.45% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Ovation Science ranks worse than 96.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ovation Science's EBITDA for the
three
months ended in Mar. 2026 was $-0.07 Mil. Ovation Science's Revenue for the
three
months ended in Mar. 2026 was $0.01 Mil. Therefore, Ovation Science's EBITDA margin for the quarter that ended in Mar. 2026 was -645.45%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ovation Science EBITDA Margin % Related Terms
Ovation Science EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ovation Science's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovation Science EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ovation Science's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ovation Science's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ovation Science (OVATF) has a EBITDA Margin % of -645.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ovation Science and its competitors. According to the industry distribution chart, Ovation Science ranks #924 out of 955 companies in the Drug Manufacturers industry, placing it in the top 96.8%.
Is Ovation Science's EBITDA Margin % too high?
Ovation Science's current EBITDA Margin % is -645.45%. Based on the distribution chart, Ovation Science ranks #924 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Ovation Science's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ovation Science ranks #924 out of 955 companies for EBITDA Margin %. This places Ovation Science in the lower half of its industry. The industry median EBITDA Margin % is 12.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ovation Science and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovation Science's current EBITDA Margin % is -645.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovation Science stock overvalued right now?
Based on GuruFocus' analysis, Ovation Science (OVATF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.04 — trading 16.7% above its estimated fair value. The current EBITDA Margin % is -645.45%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ovation Science (OVATF), the current EBITDA Margin % is -645.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ovation Science Inc. is a Canada-based company mainly engaged in the business of providing topical and transdermal cannabis products under the Ovation brand label, utilizing patented Invisicare delivery technology. The Company operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare, a patented polymer-based technology for topical and transdermal skin care products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVATF has been successfully added to your 